Bio-Gate Stock

Bio-Gate Equity

The The Equity of Bio-Gate (BIG1.DE) as of Aug 22, 2026 is 1.53 M EUR. In the previous year, The Equity was 1.75 M EUR — a change of -12.30% (lower).

Equity

1.53 MEUR

YoY

-12.30%

Last updated:

In 2026, Bio-Gate's equity was 1.53 M EUR, a -12.30% increase from the 1.75 M EUR equity in the previous year.

Access this data via the Eulerpool API

Bio-Gate Stock analysis

What does Bio-Gate do? Bio Gate AG is a company specializing in the development and production of antimicrobial surfaces. The company was founded in 2004 in Switzerland by Dr. Michael Weber as the founder and CEO of Bio Gate AG. From the beginning, the company has focused on the development of innovative antimicrobial solutions. Bio Gate's business model is based on selling antimicrobial products to various industries such as healthcare, food industry, aerospace, and electronics industry. Bio Gate is proud to offer antimicrobial products that do not contain harmful chemicals and are environmentally friendly. Bio Gate has divided itself into various divisions to offer its customers a wide range of high-quality antimicrobial products and services. One of the divisions is the medical and healthcare industry, where Bio Gate offers special antimicrobial surfaces for hospitals, medical practices, and care services. These surfaces reduce the risk of infection and ensure a hygienic and safe environment. Another division of Bio Gate is the food industry. Here, the company offers antimicrobial coatings for packaging and containers that prevent food spoilage and increase shelf life. These solutions are not only safe but also in accordance with the requirements of the food industry. The aerospace industry is another important division of Bio Gate. Bio Gate's antimicrobial solutions can prevent the spread of pathogens in confined spaces such as airplanes or spaceships. They reduce the risk of infection and increase safety for passengers and staff. Bio Gate also offers antimicrobial solutions for the electronics industry. The antimicrobial coatings can be applied to touchscreens, keyboards, and other electronic devices to reduce the risk of bacterial infections. This is especially important for users of electronic devices that are used daily, such as in schools, offices, or public areas. Bio Gate's product range includes a variety of antimicrobial solutions, such as antimicrobial paints, coatings, and fabrics. The solutions are effective not only against bacteria but also against viruses and fungi. All products are safe and free of harmful chemicals. Bio Gate AG is a company that is constantly working to improve its products and services and develop new innovative solutions. In 2016, Bio Gate received the prestigious German Design Award for its antimicrobial material. The company maintains close cooperation with customers, suppliers, and research institutions to continuously improve its solutions and offer customers the best possible solutions. In summary, Bio Gate AG is an innovative company specializing in antimicrobial solutions. It offers a wide range of antimicrobial products and services for various industries. Bio Gate is constantly working to improve its products and develop new innovative solutions to offer customers the best possible solutions. Bio-Gate is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bio-Gate's Equity

Bio-Gate's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bio-Gate's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bio-Gate's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bio-Gate's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bio-Gate’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bio-Gate stock

The Equity of Bio-Gate is 1.53 M EUR in 2026.

The Equity of Bio-Gate changed from 1.75 M EUR to 1.53 M EUR, representing a -12.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bio-Gate since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bio-Gate historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bio-Gate

All Key Metrics — Bio-Gate